The Software Layer of Imperium

Ginkgo Bioworks (DNA) is the software layer of Adam O’Dell’s Imperium pitch, the company he calls the Microsoft of the DNA revolution. O’Dell’s presentation builds a three-layer stack modeled on the personal-computer era, and Ginkgo sits in the middle slot, the operating system between the silicon layer that writes DNA and the apps that put it to work. The teaser buy price in the pitch is $8.32, matching the November 17 close, so this is a name the presentation asks you to consider right now.

The “Microsoft” framing is borrowed, not original to Ginkgo. It comes from a 2015 comment by the chief executive of Twist Bioscience, who said of the two companies, “We’re Intel, they’re Microsoft.” At the time both were startups, and the line captures why a platform layer matters: a standardized middle layer lets an ecosystem of applications build on top of it.

From $20 Billion to $539 Million

The stock’s history is the first thing an investor should understand. Ginkgo was founded by five MIT PhDs and, at its 2021 SPAC-era peak, was briefly worth around $20 billion. Today it is worth roughly $539 million, one of the steeper falls of that boom. The SPAC-era projections, which promised a fast-growing foundry business selling custom molecules, did not materialize as pitched, and the share count grew through heavy dilution along the way.

That history matters because it sets expectations. This is not a stock that has compounded steadily. It is a stock that rode a bubble up, came down hard, and is now trying to rebuild on a different business model.

The Autonomous-Lab Pivot

The rebuild is the real story. Instead of selling custom molecules, Ginkgo now sells autonomous DNA factories: robotic lab equipment that runs experiments for AI and pharmaceutical companies. The logic is that other companies want to design and test biology at scale, and Ginkgo offers them the lab infrastructure to do it without building the labs themselves.

The traction is concrete rather than theoretical. Ginkgo’s first autonomous-lab sale went to Novo Nordisk, and the company has new government wins with ARPA-H and the NSF. Those are serious customers, and they suggest the pivot has genuine demand behind it even if the revenue base is still small.

The Turnaround Case and the Risks

The bull case is that Ginkgo becomes the operating system for automated biology, and the Novo Nordisk sale plus government wins are early proof. For the other half of the stack, see our Twist Bioscience stock piece, and for the underlying field, our synthetic biology explainer. The apps layer is covered in our Absci AI drug discovery teardown.

The honest read is that this is a speculative turnaround bet, not a compounding monopoly. Thermo Fisher and roughly a dozen autonomous-lab startups are competing for the same customers, and the company’s record includes missed SPAC-era projections and heavy dilution. O’Dell is a real analyst with a real track record; he teased Palantir in the $20s in spring 2024 and watched it become the best-performing S&P 500 stock of 2024. But a strong overall record does not make every name in the stack a guaranteed winner.

For most investors, Ginkgo is a watchlist idea rather than a core holding. The pivot is genuine and the customers are real, which makes it worth following. The “Microsoft” label, though, describes a 2015 startup relationship more than it describes today’s competitive position. Keep the position size appropriate for a speculative name.

What to Watch for Next

The clearest signals for this stock going forward are follow-through on the pivot. The first autonomous-lab sale to Novo Nordisk is the proof point that matters most, because it shows a serious buyer paying for the new product line rather than just expressing interest. New ARPA-H and NSF wins add government validation, but the question is whether those wins turn into a recurring, growing revenue stream.

The other thing to watch is dilution. One of the hardest parts of Ginkgo’s story is that the share count grew through heavy dilution during the SPAC years, which means the company has to grow fast just to hold the value of each share steady. A turnaround that grows revenue while continuing to dilute shareholders is a weaker outcome than the same revenue growth with a stable share count.

O’Dell’s framing leans on the “Microsoft of the $65 trillion DNA revolution” line, and it is worth keeping the scale of that claim in perspective. The pitch is asking you to imagine a platform company on the scale of Microsoft, while the actual business is a small, recently re-pivoted tools company finding its first customers. That is not a reason to dismiss the idea. It is a reason to size it as a speculation and to let the revenue follow-through, rather than the label, do the talking.

Ready to see the research? Click here to access Adam O’Dell’s report.


NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.